Key facts
- BMRN - BIOMARIN PHARMACEUTICAL INC has 27 insiders with reported activity on this page.
- Net insider value flow over the last year: -$3,154,466.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 27 Insiders of BIOMARIN PHARMACEUTICAL INC
- Symbol
- BMRN on Nasdaq
- Location
- Novato, CA
Change
- Buy value: ; sell value: $3,154,465.
- Net share flow: -52,154.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$3,154,466.
Buys
$0
Shares: 0
Insiders: 0
Sells
$3,154,466
Shares: 52,154
Insiders: 3
Net
-$3,154,466
Shares: -52,154
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 52,154 | $0 | $3,154,466 | -$3,154,466 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
BIOMARIN PHARMACEUTICAL INC executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | $55,578,092 | Mixed | 20 May 2024 | ||
| Henry J. Fuchs | President, Worldwide R&D | $15,712,783 | Mixed | 13 Sep 2024 | ||
| Alexander Hardy | Chief Executive Officer, Director | $13,440,443 | Mixed | 17 Mar 2026 | ||
| Brian Mueller | EVP, Chief Financial Officer | $7,721,922 | Mixed | 17 Mar 2026 | ||
| Richard A. Meier | Director | $7,659,984 | Mixed | 31 Dec 2025 | ||
| Elaine J. Heron | Director | $7,466,785 | Mixed | 03 Jun 2024 | ||
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | $5,535,652 | Filing P/S | 02 May 2024 | ||
| Charles Greg Guyer | EVP, Chief Technical Officer | $5,268,846 | -$996,744 | -16% | Mixed | 17 Mar 2026 |
| George Eric Davis | EVP, Chief Legal Officer | $4,919,427 | -$1,599,103 | -25% | Mixed | 18 Mar 2026 |
| David E. I. Pyott | Director | $3,833,238 | Mixed | 21 May 2024 | ||
| Bryan Lawlis V | Director | $3,194,033 | Mixed | 23 May 2023 | ||
| Gregory R. Friberg | EVP, Chief R&D Officer | $2,790,399 | -$558,619 | -17% | Filing P/S | 07 May 2026 |
| Robert J. Hombach | Director | $2,636,972 | Mixed | 20 May 2025 | ||
| Dennis Slamon | Director | $2,623,169 | Mixed | 18 Mar 2024 | ||
| Willard H. Dere | Director | $2,453,071 | Mixed | 20 May 2025 | ||
| Cristin Hubbard | EVP, Chief Commercial Officer | $2,399,243 | Median | 20 May 2026 | ||
| Elizabeth M. Anderson | Director | $2,169,661 | Mixed | 20 May 2025 | ||
| Maykin Ho | Director | $1,764,069 | Mixed | 20 May 2025 | ||
| Andrea Acosta | GVP, Chief Accounting Officer | $1,746,598 | Mixed | 30 Apr 2021 | ||
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | $1,522,002 | Mixed | 20 Jan 2026 | ||
| Mark J. Alles | Director | $1,454,856 | Mixed | 23 May 2023 | ||
| Barbara W. Bodem | Director | $853,693 | Mixed | 20 May 2025 | ||
| Athena Countouriotis | Director | $853,379 | Mixed | 20 May 2025 | ||
| Mark J. Enyedy | Director | $853,379 | Mixed | 20 May 2025 | ||
| Erin E. Burkhart | GVP, Chief Accounting Officer | $840,600 | Filing P/S | 19 May 2025 | ||
| Timothy P. Walbert | Director | $642,143 | Mixed | 20 May 2025 | ||
| Clark Ian T. | Director | $401,870 | Mixed | 01 Aug 2025 |
Top shareholders of BIOMARIN PHARMACEUTICAL INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
9.1%
from 13D/G
|
19,818,301
|
$1,119,535,796 | — | 31 Mar 2026 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13D/G
13F
|
Company |
8.2%
|
15,795,383
|
$906,812,938 | $0 | 30 Jun 2025 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Vanguard Capital Management · Company |
5.2%
|
10,113,219
|
$571,295,741 | $0 | 31 Mar 2026 | |
| Capital Research Global Investors |
13D/G
13F
|
Company |
4.8%
|
9,150,655
|
$576,308,252 | -$241,913,549 | 31 Mar 2025 | |
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
4.3%
|
8,322,179
|
$450,729,215 | -$214,821,957 | 30 Sep 2025 | |
| Richard A. Meier |
3/4/5
|
Director |
0.07%
|
126,926
|
$7,659,984 | — | 31 Dec 2025 | |
| Robert J. Hombach |
3/4/5
|
Director |
0.02%
|
41,870
|
$2,636,972 | — | 20 May 2025 | |
| Willard H. Dere |
3/4/5
|
Director |
0.02%
|
38,950
|
$2,453,071 | — | 20 May 2025 | |
| Elizabeth M. Anderson |
3/4/5
|
Director |
0.02%
|
34,450
|
$2,169,661 | — | 20 May 2025 | |
| Maykin Ho |
3/4/5
|
Director |
0.01%
|
28,010
|
$1,764,069 | — | 20 May 2025 | |
| Barbara W. Bodem |
3/4/5
|
Director |
0.01%
|
13,555
|
$853,693 | — | 20 May 2025 | |
| Athena Countouriotis |
3/4/5
|
Director |
0.01%
|
13,550
|
$853,379 | — | 20 May 2025 | |
| Mark J. Enyedy |
3/4/5
|
Director |
0.01%
|
13,550
|
$853,379 | — | 20 May 2025 | |
| Timothy P. Walbert |
3/4/5
|
Director |
0.01%
|
10,196
|
$642,143 | — | 20 May 2025 | |
| Clark Ian T. |
3/4/5
|
Director |
0%
|
7,000
|
$401,870 | — | 01 Aug 2025 | |
| DODGE & COX |
13F
|
Company |
7.6%
|
14,561,759
|
$822,593,766 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
4.3%
|
8,298,475
|
$468,780,853 | — | 31 Mar 2026 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
4%
|
7,676,541
|
$429,348,929 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
3.8%
|
7,295,079
|
$412,099,013 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.3%
|
4,512,634
|
$254,918,695 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
3,819,441
|
$215,809,244 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2%
|
3,802,930
|
$214,803,851 | — | 31 Mar 2026 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.9%
|
3,575,000
|
$201,951,750 | — | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
1.9%
|
3,567,031
|
$201,501,556 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.6%
|
3,010,308
|
$170,052,299 | — | 31 Mar 2026 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1%
|
1,920,658
|
$108,497,970 | — | 31 Mar 2026 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.87%
|
1,672,491
|
$94,478,985 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.82%
|
1,587,683
|
$89,688,213 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.82%
|
1,586,384
|
$89,614,833 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.78%
|
1,496,852
|
$84,557,169 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.71%
|
1,362,752
|
$76,981,860 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.69%
|
1,321,665
|
$74,660,928 | — | 31 Mar 2026 | |
| Jones Hill Capital LP |
13F
|
Company |
0.66%
|
1,268,390
|
$71,651,351 | — | 31 Mar 2026 | |
| DnB Asset Management AS |
13F
|
Company |
0.63%
|
1,221,387
|
$68,996,152 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.62%
|
1,199,206
|
$67,743,147 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.62%
|
1,194,118
|
$67,455,726 | — | 31 Mar 2026 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.62%
|
1,193,661
|
$67,103,923 | — | 31 Mar 2026 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.61%
|
1,173,516
|
$66,291,637 | — | 31 Mar 2026 | |
| Deep Track Capital, LP |
13F
|
Company |
0.6%
|
1,150,000
|
$64,963,500 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.59%
|
1,144,892
|
$64,674,958 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.53%
|
1,024,871
|
$57,894,963 | — | 31 Mar 2026 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.51%
|
974,776
|
$55,065,096 | — | 31 Mar 2026 | |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC |
13F
|
Company |
0.49%
|
945,603
|
$53,417,113 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.49%
|
936,951
|
$52,928,377 | — | 31 Mar 2026 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.48%
|
933,879
|
$52,754,824 | — | 31 Mar 2026 | |
| River Road Asset Management, LLC |
13F
|
Company |
0.48%
|
917,612
|
$51,835,902 | — | 31 Mar 2026 | |
| LSV ASSET MANAGEMENT |
13F
|
Company |
0.46%
|
884,800
|
$49,982,000 | — | 31 Mar 2026 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.44%
|
857,010
|
$48,409,915 | — | 31 Mar 2026 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.44%
|
851,556
|
$48,104,398 | — | 31 Mar 2026 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.44%
|
850,819
|
$48,062,765 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for BIOMARIN PHARMACEUTICAL INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Cristin Hubbard | BMRN | Common Stock | Tax liability | -5.18% | -2,318 | 42,472 | 20 May 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Sale | -5.95% | $176,682 | $53.85 | -3,281 | 51,818 | 07 May 2026 | Direct |
| George Eric Davis | BMRN | Common Stock | Tax liability | -1.59% | -1,273 | 78,560 | 18 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Tax liability | -1.97% | -1,693 | 84,140 | 17 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Tax liability | -1.69% | -2,117 | 123,314 | 17 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -1.94% | -4,252 | 214,635 | 17 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Tax liability | -2.7% | -1,245 | 44,790 | 17 Mar 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Tax liability | -2.87% | -1,629 | 55,099 | 17 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Award | 50.3% | 15,410 | 46,035 | 16 Mar 2026 | Direct | ||
| Cristin Hubbard | BMRN | Stock Option (Right to Buy Common Stock) | Award | 36,680 | 36,680 | 16 Mar 2026 | Direct | |||
| Gregory R. Friberg | BMRN | Common Stock | Award | 51% | 19,150 | 56,728 | 16 Mar 2026 | Direct | ||
| Gregory R. Friberg | BMRN | Stock Option (Right to Buy Common Stock) | Award | 45,600 | 45,600 | 16 Mar 2026 | Direct | |||
| Charles Greg Guyer | BMRN | Common Stock | Award | 21.2% | 14,990 | 85,833 | 16 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Stock Option (Right to Buy Common Stock) | Award | 35,680 | 35,680 | 16 Mar 2026 | Direct | |||
| George Eric Davis | BMRN | Common Stock | Award | 22.3% | 14,570 | 79,833 | 16 Mar 2026 | Direct | ||
| George Eric Davis | BMRN | Common Stock | Tax liability | -9.91% | -7,177 | 65,263 | 16 Mar 2026 | Direct | ||
| George Eric Davis | BMRN | Stock Option (Right to Buy Common Stock) | Award | 34,690 | 34,690 | 16 Mar 2026 | Direct | |||
| Brian Mueller | BMRN | Common Stock | Award | 17.6% | 18,740 | 125,431 | 16 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Stock Option (Right to Buy Common Stock) | Award | 44,600 | 44,600 | 16 Mar 2026 | Direct | |||
| Alexander Hardy | BMRN | Common Stock | Award | 39.9% | 62,440 | 218,887 | 16 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Stock Option (Right to Buy Common Stock) | Award | 89,200 | 89,200 | 16 Mar 2026 | Direct | |||
| Charles Greg Guyer | BMRN | Common Stock | Tax liability | -11.4% | -9,109 | 70,843 | 13 Mar 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Tax liability | -8.53% | -9,945 | 106,691 | 13 Mar 2026 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -1.85% | -2,941 | 156,447 | 13 Mar 2026 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Sale | -17.1% | $996,744 | $60.46 | -16,486 | 79,953 | 11 Mar 2026 | Direct |
| Gregory R. Friberg | BMRN | Common Stock | Sale | -14.4% | $381,937 | $60.38 | -6,326 | 37,578 | 26 Feb 2026 | Direct |
| George Eric Davis | BMRN | Common Stock | Sale | -26.4% | $1,599,103 | $61.36 | -26,061 | 72,453 | 26 Feb 2026 | Direct |
| Charles Greg Guyer | BMRN | Common Stock | Award | 18.7% | 15,222 | 96,439 | 25 Feb 2026 | Direct | ||
| George Eric Davis | BMRN | Common Stock | Award | 18.3% | 15,224 | 98,514 | 25 Feb 2026 | Direct | ||
| Brian Mueller | BMRN | Common Stock | Award | 16.5% | 16,482 | 116,638 | 25 Feb 2026 | Direct | ||
| Rashmi Virendra Ramchandani | BMRN | Common Stock | Award | 25,610 | 25,610 | 20 Jan 2026 | Direct | |||
| Rashmi Virendra Ramchandani | BMRN | Stock Option (Right to Buy Common Stock) | Award | 18,220 | 18,220 | 20 Jan 2026 | Direct | |||
| Richard A. Meier | BMRN | Common Stock | Gift | -0.39% | -500 | 126,926 | 30 Dec 2025 | Direct | ||
| Alexander Hardy | BMRN | Common Stock | Tax liability | -9.42% | -16,570 | 159,388 | 01 Dec 2025 | Direct | ||
| Cristin Hubbard | BMRN | Common Stock | Award | 0.26% | 80 | 30,625 | 31 Oct 2025 | Direct | ||
| Charles Greg Guyer | BMRN | Common Stock | Award | 0.08% | 62 | 81,217 | 31 Oct 2025 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Award | 0.91% | 398 | 43,904 | 31 Oct 2025 | Direct | ||
| Gregory R. Friberg | BMRN | Common Stock | Tax liability | -7.06% | -3,304 | 43,506 | 30 Sep 2025 | Direct | ||
| Clark Ian T. | BMRN | Common Stock | Award | 7,000 | 7,000 | 01 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.